Preliminary Phase 2 data of TZP-102 for diabetic gastroparesis to be presented at ACG annual meeting

Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20^th at 8:50am in Ballroom C1.

“An orally administered ghrelin agonist (TZP-102) decreases the overall severity of symptoms of diabetic gastroparesis (GP): Phase 2 Proof of Concept Study - Preliminary results”

The presentation entitled, "An orally administered ghrelin agonist (TZP-102) decreases the overall severity of symptoms of diabetic gastroparesis (GP): Phase 2 Proof of Concept Study - Preliminary results" will summarize the beneficial effects of TZP-102 on the multi-component gastroparesis symptom complex.